Urologic Evaluation is Required
In a patient with hematuria but negative proteinuria, no dysmorphic RBCs, no cellular casts, normal creatinine, and no hypertension, you should proceed with a complete urologic evaluation including cystoscopy and imaging, as these findings indicate a non-glomerular source requiring assessment for malignancy and other urologic pathology. 1
Risk Stratification Determines Evaluation Intensity
The 2025 AUA/SUFU guideline provides a clear algorithmic approach based on risk stratification 1:
- Degree of hematuria: Quantify RBCs/HPF (3-10 = low risk, 11-25 = intermediate, >25 = high)
- Age thresholds: Men <40 years = low risk, 40-59 = intermediate, ≥60 = high; Women <60 = low risk, ≥60 = intermediate (women cannot be high-risk by age alone)
- Smoking history: <10 pack-years = low risk, 10-30 = intermediate, >30 = high
- History of gross hematuria: Elevates risk category even with lower RBC counts on repeat UA
Why Urologic Evaluation is Mandatory Here
The absence of glomerular markers (proteinuria, dysmorphic RBCs, RBC casts, elevated creatinine, hypertension) essentially rules out primary renal/glomerular disease as the source 2, 3. This clinical picture points to a urologic source requiring evaluation for:
- Urothelial malignancy (bladder, upper tract)
- Renal cell carcinoma
- Urolithiasis
- Other structural urologic pathology
Critical Pitfall to Avoid
Even when dysmorphic RBCs are present (≥40%), 34% of patients still have urologic disease, including 27% with malignancy 4. Therefore, the absence of glomerular markers makes urologic evaluation even more imperative, not less. Studies show that omitting cystoscopy and imaging in patients with elevated dysmorphic RBCs would miss 52.5% of treatment-requiring conditions 4.
Recommended Evaluation Algorithm
Based on the patient's risk category from the stratification table 1:
For all risk levels with non-glomerular hematuria:
- Upper tract imaging: CT urography (preferred) or renal ultrasound for younger/low-risk patients 5
- Cystoscopy: Essential for evaluating bladder and urethra
- Urine cytology: Consider for high-risk patients, though not for routine screening 6
Age-specific modifications 5:
- Patients ≤40 years with microscopic hematuria: Non-contrast CT or ultrasound; add cystoscopy if gross hematuria present
- Patients >40 years: Pre- and post-contrast CT plus cystoscopy regardless of microscopic vs. gross hematuria
When to Refer vs. Observe
Immediate urologic referral indicated for 6:
- Gross hematuria (any episode)
- High-grade microscopic hematuria (>50 RBCs/HPF on single UA)
- Persistent microscopic hematuria (>3 RBCs/HPF on 2 of 3 properly collected UAs)
Conservative follow-up may be considered for 5:
- Patients with <5 RBCs/HPF on three separate urinalyses (very low yield for significant pathology)
- However, this requires documented negative evaluations on repeated testing
Key Clinical Principle
The 2025 guideline emphasizes performing blood pressure measurement and serum creatinine at initial evaluation to assess for medical renal disease 1. Since your patient has normal BP and creatinine with no proteinuria or glomerular markers, nephrology referral is not indicated—proceed directly with urologic evaluation.